Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GCLC | P48506 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3192453 | 1.00 | ABCC4 (0.36) | ABCC4MAPTGCLCALDH1A1LMNA | |
| SCHEMBL3191438 | 0.95 | MAPT (0.39) | ABCC4MAPTGCLCALDH1A1LMNA | |
| SCHEMBL3191425 | 0.95 | MAPT (0.39) | ABCC4MAPTGCLCALDH1A1LMNA | |
| SCHEMBL3194889 | 0.93 | MAPT (0.42) | ABCC4MAPTGCLCALDH1A1LMNA | |
| SCHEMBL3194902 | 0.93 | MAPT (0.42) | ABCC4MAPTGCLCALDH1A1LMNA | |
| SCHEMBL3194974 | 0.89 | GCLC (0.34) | ABCC4MAPTGCLCNOS2GABRR1 | |
| SCHEMBL3194978 | 0.89 | GCLC (0.34) | ABCC4MAPTGCLCNOS2GABRR1 | |
| SCHEMBL2350587 | 0.78 | GABRR1 (0.34) | BLMGABRR1CYP1A2 | |
| SCHEMBL2350579 | 0.78 | GABRR1 (0.34) | BLMGABRR1CYP1A2 | |
| SCHEMBL6906378 | 0.77 | ACE2 (0.47) | GCLC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | NOVARTIS AG | 2010-01-28 | — | — | US | disclosed |
| US-7612055-B2 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| US-20080070885-A1 | MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2008-03-20 | — | — | US | disclosed |
| EP-1654241-B1 | MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2008-03-19 | — | — | EP | disclosed |
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | NOVARTIS AG (CH) | 2007-03-29 | — | — | US | disclosed |
| US-20060223745-A1 | Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof | BETSCHART CLAUDIA | 2006-10-05 | — | — | US | disclosed |
| EP-1682521-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| EP-1654241-A1 | MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005049585-A1 | MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005003106-A1 | MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223745-A1 | Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof | BACE1, APP, ACE | ABCC4 716/4885MAPT 550/4885GCLC 491/4885 |
| US-20070072792-A1 | Macrocyclic lactams and pharmaceutical use thereof | RPS11, MRPL21, RPS4Y1 | ABCC4 978/4885MAPT 3352/4885GCLC 2975/4885 |
| US-20100022500-A1 | Macrocyclic Lactams and Pharmaceutical Use Thereof | RPS11, MRPL21, RPS4Y1 | ABCC4 978/4885MAPT 3352/4885GCLC 2975/4885 |
| US-20080070885-A1 | MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF | BACE1, APP, BACE2 | ABCC4 691/4885MAPT 328/4885GCLC 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.